trending Market Intelligence /marketintelligence/en/news-insights/trending/zuygx9a-shvpmio4bk8mwq2 content esgSubNav
In This List

US FDA expands approval of Novartis skin disease drug

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


US FDA expands approval of Novartis skin disease drug

The U.S. Food and Drug Administration expanded the approval of Novartis AG's Cosentyx to include the treatment of moderate-to-severe scalp psoriasis.

The approval is based on the results of a phase 3 trial that demonstrated Cosentyx was more effective at treating the skin condition when compared to placebo.

Scalp psoriasis is one of the difficult-to-treat forms of psoriasis, a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales.

Approximately half of all 125 million patients with psoriasis suffer from scalp psoriasis, which can be challenging to treat with topical agents or phototherapy due to the presence of hair and other factors.

Cosentyx, also known as secukinumab, is an inflammatory treatment that is already approved for plaque psoriasis, psoriatic arthritis and ankylosing spondylitis in more than 70 countries.

Cosentyx was more recently found to be better than Johnson & Johnson's Stelara in treating moderate-to-severe plaque psoriasis, the most common type of the disease.